PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

RTOG to announce results of international Phase III clinical trial for newly diagnosed brain tumors

2011-05-20
(Press-News.org) RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy. The integration of tumor analysis with the clinical trial and international collaboration, major components of this unprecedented study, will significantly impact future trial design, ultimately leading to advances in patient care.

In the randomized trial, RTOG 0525 Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma, no significant improvement in overall patient survival or disease progression was observed for patients who received the dose-intensive (dose-dense) TMZ plus radiotherapy as compared to patients who received standard-dose TMZ plus radiotherapy. The trial did however prove the feasibility of collecting and analyzing tumor tissue prospectively in a multi-center setting.. The international trial was led by RTOG principal investigator Mark R. Gilbert, MD (University of Texas M. D. Anderson Cancer Center, Houston) and conducted in concert with the European Organization for Research and Treatment of Cancer (EORTC) and the North Central Cancer Treatment Group (NCCTG). Four presentations will report study results at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7.

"Given the promising preliminary data of improved patient outcomes using an adjuvant dose-intensive schedule of temozolomide, the trial allowed us to robustly test whether this treatment strategy provides a significant benefit over standard-dose temozolomide treatment," says Gilbert. "While dose-dense temozolomide did not demonstrate improved efficacy for patients newly diagnosed with a glioblastoma, the study results confirmed the prognostic significance of MGMT gene methylation and demonstrated the feasibility of prospective tumor tissue collection, molecular stratification and collection of patient outcomes in a large transatlantic intergroup trial."

One hundred and eighty-five facilities in North America and 24 facilities in Europe enrolled 1173 study participants. Key study eligibility criteria required that tumor tissue, obtained at the time of biopsy or surgery and with patient consent, be sent for central pathology review to confirm the tumor as a glioblastoma and as adequate to perform MGMT gene methylation analysis and molecular risk classification (to assess whether a correlation exists between these biomarkers and study participant outcomes).

Upon pathology confirmation, eligible patients were enrolled in the trial and randomized into one of two adjuvant treatment arms: Arm 1 (standard arm: TMZ days 1-5 every 28 days for up to 12 cycles/months) or Arm 2 (experimental arm: TMZ days 1-21 every 28 days for up to 12 cycles/months).

Study participants were stratified to assess correlation of their outcome with three major criteria: (1) prognostic recursive partitioning (based upon age, performance status, extent of pretreatment surgery, neurologic function and mental status), (2) MGMT status (methylated, unmethylated, or indeterminate) and (3) radiation therapy treatment (US standard vs European).

Trial co-chair for neuropathology and correlative biology Kenneth D. Aldape, MD (M.D. Anderson Cancer Center, Houston), comments, "In this trial we've demonstrated the positive correlation between clinical outcomes and molecular classification of glioblastoma, which will enable improved future prognostic prediction, spur the development of specific therapies based on tumor biology, and ultimately lead to individualization of treatment." Aldape will present findings of the tumor tissue profiling at the 2011 ASCO Annual Meeting.

"This trial was a tremendous undertaking with the complexities of confirming the presence of the MGMT gene as an eligibility criteria—the first time a molecular marker has been used in this manner—and of conducting the trial internationally," says RTOG Group Chair Walter J. Curran, MD, FACR,(Winship Cancer Institute of Emory University, Atlanta). "The collaboration with EORTC and NCCTG significantly helped to expedite trial enrollment and consequentially to expediently report trial results."

The clinical trial also included longitudinal data collection to measure neurocognitive function, symptom burden and health-related quality of life, collectively called net clinical benefits. The important correlations of these measures with outcomes shown by the trial will also be reported at the ASCO meeting, along with seven presentations regarding other RTOG trials.

RTOG 0525 was supported by Award Number U10CA021661 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. RTOG also received support from Merck to conduct this trial.

###

RTOG 0525 Abstracts

ASCO Oral Presentation #2006: RTOG 0525: A Randomized Phase III Trial Comparing Standard Adjuvant Temozolomide (TMZ) With a Dose-Dense (dd) Schedule in Newly Diagnosed Glioblastoma (GBM)
Gilbert MR1, Wang M2, Aldape K1, Stupp R3, Hegi M3, Jaeckle KA4, Brown P5, Armstrong TS6, Wefel J1, Corn BW7, Mahajan A1, Schultz CJ8, Erridge S9, Chakravarti A10, Curran WJ11, Mehta M12

ASCO Poster Discussion #2016: Clinical Utility of Neurocognitive Function (NCF), Quality of Life (QOL) and Symptom Assessment as Prognostic Factors for Survival and Measures of Treatment Effects on RTOG 0525
Armstrong TS6, Wang M2, Wefel JS1, Bottomley A9, Mendoza TR1, Coens C13, Werner-Wasik M14, Brachman DG15, Choucair AK16, Gilbert MR1

ASCO Oral Presentation #LBA2000: Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide In Patients With Newly Diagnosed Glioblastoma Aldape K1, Wang M2, Sulman E1, Hegi M3, Colman H1, Jones G17, Chakravarti A10, Mehta M12, Andrews D14, Long L14, Diefes K1, Heathcock L1, Jenkins R18, Schultz CJ8, Gilbert MR1

ASCO Poster Discussion #2017: Variation Over Time and Inter-Dependence Between Disease Progression and Death Among Patients With Glioblastoma (GBM) on RTOG 0525
Wang M2, Dignam J, Won M2, Curran W11, Mehta M12, Gilbert M1

1University of Texas M. D. Anderson Cancer Center, Houston, TX; 2 Radiation Therapy Oncology Group, American College of Radiology, Philadelphia, PA; 3University of Lausanne Hospitals (CHUV), Lausanne, Switzerland; 4Mayo Clinic Jacksonville, Jacksonville, FL; 5Mayo Clinic, Rochester, MN; 6University of Texas Health Science Center, Houston, TX; 7Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 8Medical College of Wisconsin, Milwaukee, WI; 9European Organisation for Research and Treatment of Cancer Brussels, Belgium; 10The Ohio State University Medical Center, Columbus, OH; 11Winship Cancer Institute of Emory University, Atlanta, GA; 12Northwestern University, Chicago, IL; 13EORTC Statistics, Brussels, Belguim; 14Thomas Jefferson University, Philadelphia, PA;15Arizonia Oncology, Scottsdale, AZ; 16Intermountain Medical Center, Murray, UT; 17MDxHealth, Durham, NC; 18University of California-San Francisco; 19University of Chicago.

The Radiation Therapy Oncology Group (RTOG) is administered by the American College of Radiology (ACR), and located in the ACR Center for Clinical Research in Philadelphia, PA. RTOG is a multi-institutional international clinical cooperative group funded primarily by National Cancer Institute grants CA21661, CA32115 and CA37422. RTOG has 40 years of experience in conducting clinical trials and is comprised of over 300 major research institutions in the United States, Canada, and internationally. The group currently is currently accruing to 40 studies that involve radiation therapy alone or in conjunction with surgery and/or chemotherapeutic drugs or which investigate quality of life issues and their effects on the cancer patient.

The American College of Radiology (ACR) is a national professional organization serving more than 32,000 radiologists, radiation oncologists, interventional radiologists and medical physicists with programs focusing on the practice of radiology and the delivery of comprehensive health care services.

END



ELSE PRESS RELEASES FROM THIS DATE:

Study identifies more cost-effective immune suppressant for transplants

2011-05-20
BIRMINGHAM, Ala. – In the first head-to-head comparison of the three most common drugs used at the time of a kidney transplant to prevent organ rejection, researchers found that the least expensive drug – at one-half to one-fifth the price – is as safe and effective as the other two, according to a paper published by University of Alabama at Birmingham researchers in the May 19, 2011, issue of the New England Journal of Medicine. Based at UAB, researchers in the INTAC trial spent three years following 474 patients who had undergone kidney transplants at 30 U.S. transplant ...

ASCO releases studies from upcoming annual meeting

2011-05-20
Alexandria, Va. – The American Society of Clinical Oncology (ASCO) today highlighted several studies in a press briefing from among more than 4,000 abstracts publicly posted online at www.asco.org in advance of ASCO's 47th Annual Meeting. An additional 17 plenary, late-breaking and other major studies will be released in on-site press conferences at the Annual Meeting. The meeting, which is expected to draw approximately 30,000 cancer specialists, will be held June 3-7, 2011, at McCormick Place in Chicago, Ill. The theme of this year's meeting is "Patients. Pathways. ...

FIGO's new classification of causes of abnormal uterine benefits patients

2011-05-20
Philadelphia, PA, May 18, 2011 – Abnormal uterine bleeding (AUB) in women of reproductive age may be due to a wide range of disorders or pathologies. Until now, there has been no universally accepted method for classifying such patients, which has impeded basic science and clinical investigation, as well as the practical, rational, and consistent application of medical and surgical therapy. As the result of a stringent 5-year review process, a multinational group of clinician–investigators with broad experience in the investigation of AUB has now agreed on a classification ...

Malaria risk reduced by genetic predisposition for cell suicide

2011-05-20
A human genetic variant associated with an almost 30 percent reduced risk of developing severe malaria has been identified. Scientists from the Bernhard Nocht Institute for Tropical Medicine (BNITM), Hamburg, and Kumasi University, Ghana, reveal that a variant at the FAS locus can prevent an excessive and potentially hazardous immune response in infected children. The study appears in the open-access journal PLoS Genetics on May 19. Severe malaria is a major public health burden in Sub-Saharan Africa, where approximately one million individuals die each year as a result ...

Sniff sniff: Smelling led to smarter mammals, researchers say

2011-05-20
A rose by any other name would smell as sweet; the saying is perhaps a testament to the acute sense of smell that is unique to mammals. Paleontologists have now discovered that an improved sense of smell jumpstarted brain evolution in the ancestral cousins of present-day mammals. The research will appear in the 20 May 2011 issue of the journal Science, which is published by AAAS, the international, nonprofit science society. The findings may help explain why mammals evolved such large and complex brains, which in some cases ballooned 10 times larger than relative body ...

Mammals first evolved big brains for better sense of smell

2011-05-20
Mammals first evolved their characteristic large brains to enable a stronger sense of smell, according to a new study published this week in the journal Science by paleontologists from The University of Texas at Austin, Carnegie Museum of Natural History and St. Mary's University in San Antonio. This latest study is the first to use CT technology, similar to medical scanners, to reconstruct the brains of two of the earliest known mammal species, both from the Jurassic fossil beds of China. The 3D scans revealed that even these tiny, 190-million-year-old animals had developed ...

Predicting the fate of personalized cells next step toward new therapies

Predicting the fate of personalized cells next step toward new therapies
2011-05-20
PHILADELPHIA – Discovering the step-by-step details of the path embryonic cells take to develop into their final tissue type is the clinical goal of many stem cell biologists. To that end, Kenneth S. Zaret, PhD, professor of Cell and Developmental Biology at the Perelman School of Medicine at the University of Pennsylvania, and associate director of the Penn Institute for Regenerative Medicine, and Cheng-Ran Xu, PhD, a postdoctoral researcher in the Zaret laboratory, looked at immature cells called progenitors and found a way to potentially predict their fate. They base ...

Large brains in mammals first evolved for better sense of smell

Large brains in mammals first evolved for better sense of smell
2011-05-20
Pittsburgh, Pennsylvania… Paleontologists have often wondered why mammals—including humans—evolved to have larger brains than other animals. A team of paleontologists now believe that large brains may have developed in mammals to facilitate an acute sense of smell, according to a new paper published today in the prestigious journal Science. The team also noticed enlargement in the areas of the brain that correspond to the ability to sense touch through fur; this sense is acutely developed in mammals. Scientists used high-resolution CT scans to study rare 190-million-year-old ...

Death of Osama bin Laden Highlights Importance of the Zadroga Act, Says New York Personal Injury Lawyer

2011-05-20
After the death of Osama bin Laden, New York personal injury lawyer David Perecman reaffirmed his commitment to help the heroes who are still battling illnesses connected to 9/11. For many individuals, the death of bin Laden brought closure. The death also served to rekindle memories of those who volunteered to assist at the World Trade Center site after the 9/11 attacks. The lives of many Ground Zero volunteers were changed in challenging ways. Rescue and recovery workers and others are still suffering from health consequences related to the World Trade Center disaster. "People ...

Scientists discover new drug target for squamous cell carcinoma

2011-05-20
SEATTLE – Researchers at Fred Hutchinson Cancer Research Center have discovered a new drug target for squamous cell carcinoma – the second most common form of skin cancer. Scientists in the laboratory of Valeri Vasioukhin, Ph.D., have found that a protein called alpha-catenin acts as a tumor suppressor and they also have unlocked the mechanism by which this protein controls cell proliferation. The findings by Vasioukhin and colleagues will be published May 24 in Science Signaling. For the study, the researchers studied mice that were bred to lack a copy of the gene that ...

LAST 30 PRESS RELEASES:

Pink skies

Monkeys are world’s best yodellers - new research

Key differences between visual- and memory-led Alzheimer’s discovered

% weight loss targets in obesity management – is this the wrong objective?

An app can change how you see yourself at work

NYC speed cameras take six months to change driver behavior, effects vary by neighborhood, new study reveals

New research shows that propaganda is on the rise in China

Even the richest Americans face shorter lifespans than their European counterparts, study finds

Novel genes linked to rare childhood diarrhea

New computer model reveals how Bronze Age Scandinavians could have crossed the sea

Novel point-of-care technology delivers accurate HIV results in minutes

Researchers reveal key brain differences to explain why Ritalin helps improve focus in some more than others

Study finds nearly five-fold increase in hospitalizations for common cause of stroke

Study reveals how alcohol abuse damages cognition

Medicinal cannabis is linked to long-term benefits in health-related quality of life

Microplastics detected in cat placentas and fetuses during early pregnancy

Ancient amphibians as big as alligators died in mass mortality event in Triassic Wyoming

Scientists uncover the first clear evidence of air sacs in the fossilized bones of alvarezsaurian dinosaurs: the "hollow bones" which help modern day birds to fly

Alcohol makes male flies sexy

TB patients globally often incur "catastrophic costs" of up to $11,329 USD, despite many countries offering free treatment, with predominant drivers of cost being hospitalization and loss of income

Study links teen girls’ screen time to sleep disruptions and depression

Scientists unveil starfish-inspired wearable tech for heart monitoring

Footprints reveal prehistoric Scottish lagoons were stomping grounds for giant Jurassic dinosaurs

AI effectively predicts dementia risk in American Indian/Alaska Native elders

First guideline on newborn screening for cystic fibrosis calls for changes in practice to improve outcomes

Existing international law can help secure peace and security in outer space, study shows

Pinning down the process of West Nile virus transmission

UTA-backed research tackles health challenges across ages

In pancreatic cancer, a race against time

Targeting FGFR2 may prevent or delay some KRAS-mutated pancreatic cancers

[Press-News.org] RTOG to announce results of international Phase III clinical trial for newly diagnosed brain tumors